Our finding that five of six cancer-associated CSB mutations located in the CSB-WHD, D1425N, Q1444H, A1445S, R1462L and R1467Q, sensitize cells to treatment with cisplatin, a platinum-based chemotherapeutic drug commonly used to treat a number of cancers [44,45,46], suggests that these mutations can serve as biomarkers for cancer diagnosis and treatment. Here, ERCC6 is linked to cancer.